Eton Pharmaceuticals(ETON) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results ● Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growth ● New drug application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA) and assigned a February 28, 2025 PDUFA date ● Q2 2024 Cash Flow from Operations of $1.3 million, including the payment of one-time $2.0 million NDA filing fee for ET400 ● Management ...